Troponin i and cardiovascular risk prediction in the general population: The BiomarCaRE consortium

European Heart Journal

Volumn 37, Issue 30, 2016, Pages 2428-2437

  Blankenberg, Stefan ^a,b   Salomaa, Veikko ^c   Makarova, Nataliya ^a,b   Ojeda, Francisco ^a   Wild, Philipp ^b,d   Lackner, Karl J ^d   Jørgensen, Torben ^e,f   Thorand, Barbara ^g   Peters, Annette ^b,g   Nauck, Matthias ^b,h   Petersmann, Astrid ^b,h   Vartiainen, Erkki ^c   Veronesi, Giovanni ⁱ   Brambilla, Paolo ^j   Costanzo, Simona ^k   Iacoviello, Licia ^k   Linden, Gerard ^l   Yarnell, John ^l   Patterson, Christopher C ^l   Everett, Brendan M ^m   Ridker, Paul M ^m   Kontto, Jukka ^c   Schnabel, Renate B ^a,b   Koenig, Wolfgang ^b,n,o   Kee, Frank ^l   Zeller, Tanja ^a,b   Kuulasmaa, Kari ^c   more..

^a UNIVERSITY HEART CENTER HAMBURG   (Germany)

^b DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

^c NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^d UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f Research Centre for Prevention and Health   (Denmark)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h UNIVERSITY MEDICINE GREIFSWALD   (Germany)

ⁱ UNIVERSITY OF INSUBRIA   (Italy)

^j UNIVERSITY OF MILANO BICOCCA   (Italy)

^k IRCCS NEUROMED   (Italy)

^l QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^m BRIGHAM AND WOMEN S HOSPITAL   (United States)

ⁿ UNIVERSITY HOSPITAL ULM   (Germany)

^o TECHNICAL UNIVERSITY OF MUNICH   (Germany)

more..

Author keywords

Biomarker for Cardiovascular Risk Assessment in Europe; Cardiovascular risk; High sensitivity assayed troponin I; MONICA Risk Genetics Archiving and Monograph; Mortality

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ROSUVASTATIN; TROPONIN I; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHENOTYPE; PREDICTIVE VALUE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN LOCALIZATION; SMOKING; EUROPE; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

BIOMARKERS; CARDIOVASCULAR DISEASES; EUROPE; HUMANS; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TROPONIN I;

EID: 84983447090     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehw172     Document Type: Article

References (45)

1. Amsterdam EA,Wenger NK, Brindis RG, Casey DE Jr, Ganiats TG, Holmes DR Jr, Jaffe AS, Jneid H, Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, Zieman SJ. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;130: 2354-2394.
2. Apple FS, Ler R, Murakami MM. Determination of 19 cardiac troponin I and T assay 99th percentile values from a common presumably healthy population. Clin Chem 2012;58:1574-1581.
3. Sinning C, Keller T, Zeller T, Ojeda F, Schluter M, Schnabel R, Lubos E, Bickel C, Lackner KJ, Diemert P, Munzel T, Blankenberg S, Wild PS. Association of highsensitivity assayed troponin I with cardiovascular phenotypes in the general population: the population-based Gutenberg health study. Clin Res Cardiol 2014;103:211-222.
4. de Lemos JA, Drazner MH, Omland T, Ayers CR, Khera A, Rohatgi A, Hashim I, Berry JD, Das SR, Morrow DA. Association of troponin T detected with a highly sensitive assay and cardiac structure and mortality risk in the general population. JAMA 2010;304:2503-2512.
5. Omland T, de Lemos JA, Holmen OL, Dalen H, Benth JS?, Nygard S, Hveem K, Røsjø H. Impact of sex on the prognostic value of high-sensitivity cardiac troponin I in the general population: the HUNT study. Clin Chem 2015;61:646-656.
6. Zeller T, Tunstall-Pedoe H, Saarela O, Ojeda F, Schnabel RB, Tuovinen T, Woodward M, Struthers A, Hughes M, Kee F. High population prevalence of cardiac troponin I measured by a high-sensitivity assay and cardiovascular risk estimation: the MORGAM Biomarker Project Scottish Cohort. Eur Heart J 2014;35: 271-281.
7. Neumann JT, Havulinna AS, Zeller T, Appelbaum S, Kunnas T, Nikkari S, Jousilahti P, Blankenberg S, Sydow K, Salomaa V. Comparison of three troponins as predictors of future cardiovascular events-prospective results from the FINRISK and Bioma-CaRE studies. PLoS ONE 2014;9:e90063.
8. Everett BM, Zeller T, Glynn RJ, Ridker PM, Blankenberg S. High sensitivity cardiac troponin I and B-type natriuretic peptide as predictors of vascular events in primary prevention: impact of statin therapy. Circulation 2015;131:1851-1860.
9. Saunders JT, Nambi V, de Lemos JA, Chambless LE, Virani SS, Boerwinkle E, Hoogeveen RC, Liu X, Astor BC, Mosley TH. Cardiac troponin T measured by a highly sensitive assay predicts coronary heart disease, heart failure, and mortality in the Atherosclerosis Risk in Communities Study. Circulation 2011;123:1367-1376.
10. Omland T, Pfeffer MA, Solomon SD, de Lemos JA, Røsjø H, Benth JS?, Maggioni A, Domanski MJ, Rouleau JL, Sabatine MS. Prognostic value of cardiac troponin I measured with a highly sensitive assay in patients with stable coronary artery disease. J Am Coll Cardiol 2013;61:1240-1249.
11. Everett BM, Cook NR, Magnone MC, Bobadilla M, Kim E, Rifai N, Ridker PM, Pradhan AD. Sensitive cardiac troponin T assay and the risk of incident cardiovascular disease in women with and without diabetes mellitus the Women's Health Study. Circulation 2011;123:2811-2818.
12. de Lemos JA, Christenson RH, Gottdiener JS, Kop WJ, Zhan M, Seliger SL. Association of serial measures of cardiac troponin T using a sensitive assay with incident heart failure and cardiovascular mortality in older adults. JAMA 2010;304: 2494-2502.
13. Everett BM, Brooks MM, Vlachos HE, Chaitman BR, Frye RL, Bhatt DL. Troponin and cardiac events in stable ischemic heart disease and diabetes. New Engl J Med 2015;373:610-620.
14. Conroy R, Pyö rälä K, Fitzgerald Ae, Sans S, Menotti A, De Backer G, De Bacquer Dr, Ducimetiere P, Jousilahti P, Keil U. Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project. Eur Heart J 2003;24: 987-1003.
15. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z?, Verschuren M, Albus C, Benlian P, Boysen G, Cifkova R. European guidelines on cardiovascular disease prevention in clinical practice (version 2012). Eur Heart J 2012;33:1635-1701.
16. Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R, Greenland P, Lackland DT, Levy D, O'Donnell CJ, Robinson JG, Schwartz JS, Shero ST, Smith SC Jr, Sorlie P, Stone NJ, Wilson PW, Jordan HS, Nevo L, Wnek J, Anderson JL, Halperin JL, Albert NM, Bozkurt B, Brindis RG, Curtis LH, DeMets D, Hochman JS, Kovacs RJ, Ohman EM, Pressler SJ, Sellke FW, Shen WK, Smith SC Jr, Tomaselli GF. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129(25 Suppl. 2):S49-S73.
17. Zeller T, Hughes M, Tuovinen T, Schillert A, Conrads-Frank A, den Ruijter H, Schnabel RB, Kee F, Salomaa V, Siebert U. BiomarCaRE: rationale and design of the European BiomarCaRE project including 300,000 participants from 13 European countries. Eur J Epidemiol 2014;29:777-790.
18. Ridker PM, Danielson E, Fonseca F, Genest J, Gotto AM Jr, Kastelein J, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008;359:2195.
19. Kulathinal S, Niemela M, Niiranen T, Saarela O, Palosaari T, Tapanainen H, Kuulasmaa K. Contributors from Participating Centres, for the MORGAM Project. Description of MORGAM Cohorts. MORGAM Project. e-publications [Internet]. 2005-; (2). URN:NBN:fi-fe20051214. http://www.thl.fi/publications/morgam/manual/contents.htm (July 28, 2015).
20. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
21. Lipsitz SR, Leong T, Ibrahim J, Lipshultz S. A partial correlation coefficient and coefficient of determination for multivariate normal repeated measures data. J R Stat Soc D 2001;50:87-95.
22. Fox J. Effect displays in R for generalised linear models. J Stat Softw 2003;8:1-27.
23. Geraci M, Bottai M. Linear quantile mixed models. Stat Comput 2014;24:461-479.
24. Geraci M. Linear quantile mixed models: the lqmm package for Laplace quantile regression. J Stat Softw 2014;57:1-29.
25. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-2546.
26. Harrell FE, Lee KL, Mark DB. Tutorial in biostatistics multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-387.
27. Pencina MJ, D'Agostino RB, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008;27:157-172.
28. Pencina MJ, D'Agostino RB, Steyerberg EW. Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers. Stat Med 2011; 30:11-21.
29. Leening MJG, Vedder MM, Witteman JCM, Pencina MJ, Steyerberg EW. Net reclassification improvement: computation, interpretation, and controversies: a literature review and clinician's guide. Ann Intern Med 2014;160:122-131.
30. Antolini L, Nam B-H, D'Agostino RB. Inference on correlated discrimination measures in survival analysis: a nonparametric approach. Commun Stat Theory Methods 2004;33:2117-2135.
31. Demler OV, Paynter NP, Cook NR. Tests of calibration and goodness-of-fit in the survival setting. Stat Med 2015;34:1659-1680.
32. R Development Core Team. A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2008.
33. Collaboration ERF. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. The Lancet 2010;375:132-140.
34. Everett BM, Berger JS, Manson JE, Ridker PM, Cook NR. B-type natriuretic peptides improve cardiovascular disease risk prediction in a cohort of women. J Am College Cardiol 2014;64:1789-1797.
35. Douglas PS, Felker GM. N-Terminal Pro-B-type natriuretic peptide: a risk predictor for all. J Am Coll Cardiol 2014;64:1798-1800.
36. Ledwidge M, Gallagher J, Conlon C, Tallon E, O'Connell E, Dawkins I, Watson C, O'Hanlon R, Bermingham M, Patle A. Natriuretic peptide-based screening and collaborative care for heart failure: the stop-HF randomized trial. JAMA 2013;310: 66-74.
37. Huelsmann M, Neuhold S, Resl M, Strunk G, Brath H, Francesconi C, Adlbrecht C, Prager R, Luger A, Pacher R. PONTIAC (NT-proBNP Selected PreventiOn of cardiac eveNts in a populaTion of dIabetic patients without A history of Cardiac disease): a prospective randomized controlled trial. J Am Coll Cardiol 2013;62: 1365-1372.
38. van der Velde M, Matsushita K, Coresh J, Astor BC, Woodward M, Levey A, de Jong P, Gansevoort RT, Levey AS, de Jong PE. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. Kidney Int 2011; 79:1341-1352.
39. Consortium CKDP. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. The Lancet 2010;375:2073-2081.
40. Janes H, Pepe MS, Bossuyt PM, Barlow WE. Measuring the performance of markers for guiding treatment decisions. Ann Intern Med 2011;154:253-259.
41. Goff DC, Lloyd-Jones DM, Bennett G, O'Donnell C, Coady S, Robinson J. 2013 ACC/AHA guideline on the assessment of cardiovascular risk. J Am Coll Cardiol 2014;63:2935-2959.
42. White HD, Tonkin A, Simes J, Stewart R, Mann K, Thompson P, Colquhoun D, West M, Nestel P, Sullivan D, Keech AC, Hunt D, Blankenberg S, Investigators LS. Association of contemporary sensitive troponin I levels at baseline and change at 1 year with long-term coronary events following myocardial infarction or unstable angina: results from the LIPID Study (Long-Term Intervention With Pravastatin in Ischaemic Disease). J Am Coll Cardiol 2014;63:345-354.
43. Laatikainen T, Critchley J, Vartiainen E, Salomaa V, Ketonen M, Capewell S. Explaining the decline in coronary heart disease mortality in Finland between 1982 and 1997. Am J Epidemiol 2005;162:764-773.
44. Salomaa V, Ketonen M, Koukkunen H, Immonen-Räihä P, Jerkkola T, Kärjä-Koskenkari P, Mähönen M, Niemelä M, Kuulasmaa K, Palomäki P. Decline in out-of-hospital coronary heart disease deaths has contributed the main part to the overall decline in coronary heart disease mortality rates among persons 35 to 64 years of age in Finland the Finami Study. Circulation 2003;108: 691-696.
45. Marsik C, Kazemi-Shirazi L, Schickbauer T, Winkler S, Joukhadar C, Wagner OF, Endler G. C-reactive protein and all-cause mortality in a large hospital-based cohort. Clin Chem 2008;54:343-349.